<?xml version="1.0" encoding="UTF-8"?><xml>
<annotation_summary>gene summary </annotation_summary>
<gene_annotation>
    <description>gene annotation description</description>
</gene_annotation>
<variant_effect>
    <effect>Activating</effect>
    <description>mutation effect</description>
</variant_effect>
<cancer_type type="breast cancer" relevant_to_patient_disease="Yes">
    <investigational_therapeutic_implications>
        <sensitive_to>
            <treatment>
                <drug>
                    <name>AZD5363</name>
                    <fda_approved>No</fda_approved>
                </drug>
            </treatment>
            <level_of_evidence_for_patient_indication>
                <level>4</level>
                <description>description</description>
            </level_of_evidence_for_patient_indication>
            <description>desc</description>
        </sensitive_to>
    </investigational_therapeutic_implications>
</cancer_type>
<cancer_type type="All tumors" relevant_to_patient_disease="Yes">
    <investigational_therapeutic_implications>
        <general_statement>
            <sensitivity>
                <description>description</description>
            </sensitivity>
        </general_statement>
        <sensitive_to>
            <treatment>
                <drug>
                    <name>GSK2141795</name>
                    <fda_approved>No</fda_approved>
                </drug>
            </treatment>
            <level_of_evidence_for_patient_indication>
                <level>4</level>
                <description>descp</description>
            </level_of_evidence_for_patient_indication>
            <description>descp</description>
        </sensitive_to>
    </investigational_therapeutic_implications>
    <clinical_trial>
        <trial_id>NCT02117167</trial_id>
        <title>Intergroup Trial UNICANCER UC 0105-1305/ IFCT 1301: Efficacy of Targeted Drugs Guided by Genomic Profils in Metastatic NSCLC Patients</title>
        <purpose>Open label multicentric randomized phase II trial, using high throughput genome analysis as
      a therapeutic decision tool, aimed at comparing a targeted treatment administered according
      to the identified molecular anomalies of the tumor with a standard treatment (pemetrexed in
      Non squamous disease and erlotinib in squamous disease)</purpose>
        <recruiting_status>Recruiting</recruiting_status>
        <eligibility_criteria>Screening phase:

        Inclusion Criteria:

          -  histologically proven NSCLC

          -  Metastatic relapse or stage IV at diagnosis, or stage IIIb not amenable to surgery or
             radiotherapy.

          -  No EGFR-activating mutation or ALK translocation.

          -  primary tumor or metastases that can be biopsied, excluding bone.

          -  Age &gt; 18 years

          -  WHO Performance Status 0/1

          -  Chemo-naïve patients eligible to a first line platinum-based chemotherapy

          -  No tumor progression observed with the current line of treatment

          -  measurable target lesion or evaluable diseases RECIST

        Exclusion criteria

          -  Spinal cord compression and/or symptomatic or progressive brain metastases

          -  Abnormal coagulation contraindicating biopsy

          -  Inability to swallow

          -  Major problem with intestinal absorption

          -  Any clinically important abnormalities in rhythm, conduction or morphology of resting
             ECG

          -  Any factors increasing the risk of QTc prolongation or arrhythmic events

          -  Experience of any of the following in the preceding 12 months: coronary artery bypass
             graft, angioplasty, vascular stent, myocardial infarction, past or current
             uncontrolled angina pectoris, congestive heart failure NYHA Grade &gt;=2, torsades de
             pointes, current uncontrolled hypertension, cardiomyopathy

          -  Past medical history of interstitial lung disease, drug-induced interstitial disease,
             radiation pneumonitis which requires steroid treatment or any evidence of clinically
             interstitial lung disease

          -  Previous or current malignancies of other histologies within the last 5 years,

          -  Evidence of severe or uncontrolled systemic disease (active bleeding diatheses, or
             active Hepatitis B, C and HIV)

          -  Diagnosis of diabetes mellitus type I or II

          -  diagnosis of acne rosacea, severe psoriasis and severe atopic eczema

          -  Prior exposure to anthracyclines or mitoxantrone with cumulative exposure in excess
             of 360 mg/m² for doxorubicin, 720 mg/m² for epirubicin, or 72 mg/m² for mitoxantrone

          -  History of retinal degenerative disease, eye injury or corneal surgery in the
             previous 3 months, past history of central serous retinopathy or retinal vein
             occlusion, intraocular pressure &gt;21 mmHg, or uncontrolled glaucoma.

          -  History of heamorrhagic or thrombotic stroke, TIA or other CNS bleeds

          -  Renal disease including glomerulonephritis, nephritic syndrome, Fanconi syndrome,
             renal tubular acidosis

          -  Patients using drugs that are known potent inhibitors or potent inducers or
             substrates of cytochrome P450

        Randomized phase:

        Inclusion criteria

          -  Patients who received 4 cycles of an induction platinum-based chemotherapy and who
             have a SD or a PR at randomization

          -  presenting at least one genomic alteration from the predefined list

          -  Age &gt; 25 years for patients planned to receive AZD4547

          -  28-day washout period from chemo prior to randomization and grade &gt;=1 residual
             toxicities,

        Exclusion criteria

          -  Life expectancy &lt; 3 months.

          -  Disease progression occuring at any time during chemotherapy and before randomization
             or toxicity that led to the discontinuation of the platinium based chemotherapy
             before 4 full cycles have been delivered

          -  Less than 28 days from radiotherapy, less than 2 weeks from palliative radiation

          -  Patients previously treated with a targeted agent in the same class as agents tested
             in this study

          -  Toxicities of grade &gt;=2 from any previous anti-cancer therapy

          -  Altered haematopoietic or organ function,

          -  Mean resting corrected QT interval (QTc)&gt;480msec (or QTcF &gt;450 msec) obtained from 3
             consecutive ECGs

          -  LVEF &lt;55% (MUGA scan or Echocardiogram),

          -  Altered ophthalmic conditions confirmed by an ophthalmology specialist for patients
             likely to be treated with AZD4547 orAZD8931 or Selumetinib :

          -  Patients using non-substitutable drugs, that are known to prolong QT interval or
             induce Torsades de Pointes, when they are supposed to be treated with vandetanib,
             AZD5363 or AZD8931</eligibility_criteria>
        <phase>Phase 2</phase>
        <biomarker>AKT1 Activating mutations</biomarker>
        <intervention>Selumetinib</intervention>
        <intervention>Erlotinib</intervention>
        <intervention>AZD5363</intervention>
        <intervention>AZD4547</intervention>
        <intervention>AZD8931</intervention>
        <intervention>AZD2014</intervention>
        <intervention>Vandetanib</intervention>
        <intervention>Pemetrexed</intervention>
        <condition>All tumors</condition>
    </clinical_trial>
</cancer_type>
</xml>
